The tumour microenvironment and implications for cancer immunotherapy (Q36521830)

14 August 2017

1 reference

title

The tumour microenvironment and implications for cancer immunotherapy (English)

1 reference

14 August 2017

1 reference

Howard L Kaufman

1 reference

14 August 2017

Christian A Petrulio

1 reference

14 August 2017

Seunghee Kim-Schulze

series ordinal

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

671-684

1 reference

Know thy neighbor: stromal cells can contribute oncogenic signals

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Tumor-infiltrating T lymphocytes: friends or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

The role of Fas/FasL in immunosuppression induced by human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

22. Immune responses to malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

MHC class I antigens, immune surveillance, and tumor immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Regulation and role of TGF beta production in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Cytokine profiles in spontaneously regressing basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

S100A7 and the progression of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Indoleamine 2,3 dioxygenase and regulation of T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Targeted cancer therapy using radiolabeled monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Anti-angiogenic therapy as a cancer treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Stromal fibroblasts in cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Hypoxia and anemia: effects on tumor biology and treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Relevance of tumor microenvironment for progression, therapy and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Microenvironmental and cellular consequences of altered blood flow in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Identifiers

DOI

10.1517/14712598.6.7.671

1 reference

14 August 2017

1 reference